Clinical trial
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination…
NCT00377182 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00377182 |
|---|---|
| Title | A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection. |
| Official title | A Randomized, Double-blind Study to Evaluate the Safety and Tolerability of the HCV Polymerase Inhibitor Pro-drug in Combination With Pegasys, With or Without Copegus, Versus Pegasys Plus Copegus, in Treatment-naïve Patients With Chronic Hepatitis C, Genotype 1 |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg |
| Enrollment | 107 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Sep 18, 2006 |
| Last update posted | Nov 2, 2016 |
| Countries | Puerto Rico, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: